Kyverna Therapeutics reported registrational‑trial results showing its patient‑specific CD19 CAR‑T improved mobility and stiffness in stiff person syndrome (SPS), meeting primary and secondary endpoints. The company said it will pursue a U.S. marketing application in H1 2026 based on the registrational data and characterizes the outcome as highly statistically significant. The results position Kyverna to seek the first FDA approval of a CAR‑T for an autoimmune indication.